



To expedite processing, please send the following information with prescription.

- |   |   |
|---|---|
| <input type="checkbox"/> Referral Form              | <input type="checkbox"/> List of Tried and Failed Meds<br>(Including other Biologics) |
| <input type="checkbox"/> Demographic Sheet          | <input type="checkbox"/> Prescription Insurance Card<br>(Front & Back)                |
| <input type="checkbox"/> Most Recent Clinical Notes |   |

Bio-Coordinator or Primary Point of Contact at Clinic:

Name: \_\_\_\_\_

Email: \_\_\_\_\_

Direct Phone Line: \_\_\_\_\_

Cell (optional, but preferred): \_\_\_\_\_

**Genefic Specialty Pharmacy**  
**2577 Mall Road, Suite B**  
**Florence, AL, 35630**

Phone: (833) 928-7660  
Fax: (833) 928-7661  
Website: GeneficRx.com

<h1 style="margin:0;">Adalimumab Biosimilar Idacio Yuflyma Yusimry Enrollment Form</h1>	Prescriber: _____		NPI: _____
	Supervising Physician: _____		NPI: _____
	Address: _____		Tax ID: _____
	Phone: _____	Fax: _____	
	Contact: _____		

PATIENT INFORMATION					
Name: _____	<input type="checkbox"/> M <input type="checkbox"/> F <input type="checkbox"/> Trans M <input type="checkbox"/> Trans F <input type="checkbox"/> Other	DOB: ____/____/____	SS#: _____		
Street: _____	City: _____	State: _____	ZIP: _____		
Phone: _____	Alt. Phone: _____	<input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Other: _____	Wt.: _____	Ht.: _____	

**PRESCRIPTION**

Has the patient received a loading dose/starter kit?  Yes Start Date: \_\_\_\_/\_\_\_\_/\_\_\_\_  No Ship to:  Patient's Home  Doctor's Office  Other: \_\_\_\_\_

Drug	Directions & Quantity	Refills
<b>Idacio®</b> <input type="checkbox"/> Psoriasis/Uveitis Starter Package <input type="checkbox"/> Crohn's/UC Starter Package <input type="checkbox"/> 40 mg/0.8 mL Pen <input type="checkbox"/> 40 mg/0.8 mL Pre-filled Syringe	<b>INITIAL/LOADING DOSES: ***WEIGHT REQUIRED***</b> <input type="checkbox"/> PSORIASIS/UEVITIS: Inject 80 mg on SQ day 1, 40 mg on day 8, then 40 mg every other week (Quantity: 4) <input type="checkbox"/> CROHN'S/UC: Inject 160 mg on SQ on day 1, then 80 mg on day 15 (Quantity: 6) ***Intended for ped CD patients ≥ 40 kg (88 lbs)*** <b>MAINTENANCE DOSES:</b> <input type="checkbox"/> Inject 40 mg SQ every other week (Quantity: 2) <input type="checkbox"/> Inject 40 mg SQ weekly (Quantity: 4) <input type="checkbox"/> Inject 80 mg SQ every other week (Quantity: 4)	
<b>Yuflyma®</b> <input type="checkbox"/> 40 mg/0.4 mL Autoinjector	<b>INITIAL/LOADING DOSES: ***WEIGHT REQUIRED***</b> <input type="checkbox"/> PSORIASIS/UEVITIS: Inject 80 mg on SQ day 1, 40 mg on day 8, then 40 mg every other week (Quantity: 4) <input type="checkbox"/> CROHN'S/UC/HS: Inject 160 mg on SQ on day 1, then 80 mg on day 15 (Quantity: 6) ***Intended for ped CD patients ≥ 40 kg (88 lbs)*** <b>MAINTENANCE DOSES:</b> <input type="checkbox"/> Inject 40 mg SQ every other week (Quantity: 2) <input type="checkbox"/> Inject 40 mg SQ weekly (Quantity: 4) <input type="checkbox"/> Inject 80 mg SQ every other week (Quantity: 4)	
<b>Yusimry™</b> <input type="checkbox"/> 40 mg/0.8 mL Pen	<b>INITIAL/LOADING DOSES: ***WEIGHT REQUIRED***</b> <input type="checkbox"/> PSORIASIS/UEVITIS: Inject 80 mg on SQ day 1, 40 mg on day 8, then 40 mg every other week (Quantity: 4) <input type="checkbox"/> CROHN'S/UC/HS: Inject 160 mg on SQ on day 1, then 80 mg on day 15 (Quantity: 6) ***Intended for ped CD patients ≥ 40 kg (88 lbs)*** <b>MAINTENANCE DOSES:</b> <input type="checkbox"/> Inject 40 mg SQ every other week (Quantity: 2) <input type="checkbox"/> Inject 40 mg SQ weekly (Quantity: 4) <input type="checkbox"/> Inject 80 mg SQ every other week (Quantity: 4)	

**MEDICAL INFORMATION**

**\*\*\*PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY\*\*\***

PREVIOUS THERAPIES:	Tried & Failed (Duration):	Not Tolerated:	Contraindication:
<input type="checkbox"/> Methotrexate	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____
<input type="checkbox"/> Enbrel	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____
<input type="checkbox"/> _____	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/> (_____)	<input type="checkbox"/>	_____

<input type="checkbox"/> H20.9 Iridocyclitis (Uveitis), Unspecified	<input type="checkbox"/> K50.90 Crohn's disease unspecified, without complications	<input type="checkbox"/> K51.90 Ulcerative Colitis unspecified, without complications
<input type="checkbox"/> L40.0 Psoriasis Vulgaris (Plaque Psoriasis)	<input type="checkbox"/> L40.50 Arthropathic Psoriasis, unspecified (Psoriatic Arthritis)	<input type="checkbox"/> L73.2 Hidradenitis suppurativa
<input type="checkbox"/> M05.9 Rheumatoid Arthritis with Rheumatoid Factor, unspecified	<input type="checkbox"/> M06.09 Rheumatoid Arthritis without Rheumatoid Factor, multiple sites	<input type="checkbox"/> M06.9 Rheumatoid Arthritis, unspecified
<input type="checkbox"/> M08.09 Unspecified juvenile RA, multiple sites (pcJIA)	<input type="checkbox"/> M45.9 Ankylosing Spondylitis, unspecified	<input type="checkbox"/> Other: _____

Date of Diagnosis: \_\_\_\_/\_\_\_\_/\_\_\_\_ Allergies: \_\_\_\_\_

Active TB is ruled out:  Yes  No Date: \_\_\_\_/\_\_\_\_/\_\_\_\_ Hep B ruled out/treated:  Yes  No Date: \_\_\_\_/\_\_\_\_/\_\_\_\_

**Additional Clinical Information:**  
 \_\_\_\_\_  
 \_\_\_\_\_

**INJECTION TRAINING**

Patient has received pen and injection training  Physician's office to provide injection training  enefic to coordinate injection training

**PRESCRIBER SIGNATURE**

**To Prescriber:** By signing this form and utilizing our services, you are also authorizing enefic to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.

Prescriber: \_\_\_\_\_ Date: \_\_\_\_/\_\_\_\_/\_\_\_\_

**CONFIDENTIALITY NOTICE**

**IMPORTANT:** This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.